Biopharmaceutical Oral Drug Delivery Market Size: Global Industry Demand, Growth, share & Forecast 2027

Biopharmaceutical oral drug delivery Market Overview

Biopharmaceutical substances are drugs originated from life forms and are made by using biotechnological means. Biopharmaceutical products are proteins (antibodies) and nucleic acids (DNA or RNA). Oral drug delivery route is an easy form of drug delivery and is the most chosen route of drug administration.

Market Size & Forecast

Biopharmaceutical oral drug delivery is anticipated to record a significant CAGR over the forecast period. The increasing R&D activities for new drugs and new combinations of drugs are expected to drive the global biopharmaceutical oral drug delivery market. The ease of administration driven by patient preferences is projected to drive the growth of biopharmaceutical oral drug delivery market.

With pharmaceutical companies increasingly turning to oral drug delivery to extend the revenue-earning lifetime of their biggest products, and seeking to tap into the growing elderly population that requires products with a level of ease-of-use and cost benefit, it’s no surprise that the oral drug delivery market is expected to grow at an exponential rate.

The global biopharmaceutical oral drug delivery market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

North America and Europe are expected to be the leading markets for biopharmaceutical oral drug delivery. Presence of key players, better R&D facilities and better compensation policies are the aspects pushing the growth of this market. Increasing incidences of life-style diseases are also estimated to drive the growth of biopharmaceutical market in this region.

Asia Pacific is estimated to be quickest growing market segment especially of India owing to the presence of key market players and increasing need for custom-made medicines. Rising focus of companies on biopharmaceuticals products is fueling the growth of biopharmaceutical oral drug delivery market as well.

Market Segmentation

Our-in depth analysis of the global anti-malarial drugs market and biopharmaceutical oral drug delivery market includes the following segments:

By Bio-pharmaceutics Delivery System (BCS)

Class I – High Solubility, High Permeability
Class II – Low Solubility, High Permeability
Class III – High Solubility, Low Permeability
Class IV – Low Solubility, Low Permeability

By Therapeutics

Anti-infective Agents
Antineoplastic Agents
Biologic and Immunologic Agents
Cardiovascular Agents
Central Nervous System Agents
Dermatological Agents
Endocrine and Metabolic Agents
Gastrointestinal Agents
Nutrients and Nutritional Agents
Ophthalmic and Optic Agents
Radiopaque Contrast Medium
Renal and Genitourinary Agents
Respiratory Agents

By Formulation

Physical mixture
Prodrug
Lipid-based
Solid dispersion
Co-solvent

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Specialty Pharmacy

By Region

Global anti-malarial drugs market and biopharmaceutical oral drug delivery market is further classified on the basis of region as follows:

North America (United States, Canada), Market size, Y-O-Y growth Market size, Y-O-Y growth & Opportunity Analysis, Future forecast & Opportunity Analysis
Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX (Belgium, Netherlands, Luxembourg), NORDIC (Norway, Denmark, Sweden, Finland), Poland, Russia, Rest of Europe), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis

Growth Drivers & Challenges

Safety and efficiency associated with the biopharmaceutical products are the factors driving the growth of this market. As biopharmaceutical drugs are more biocompatible with living systems than synthetic drugs, there are an increasing number of pharmaceutical companies developing products in this category.

However, if biopharmaceutical drugs are given orally, they get degraded by enzymes and acidic environment in GI tract (Gastrointestinal tract). These products cannot cross epithelial barrier of small intestine because of the large size of their molecules thereby decreasing the bio-obtainability of orally induced biopharmaceuticals at the site of interest. With an increase in R&D by various pharmaceutical companies, there has been a rise in adoption of oral drug delivery technologies which offer various benefits such as lower dosage frequency, fewer adverse gastrointestinal effects, enhanced patient compliance; uniform drug effect, improved efficacy and safety of medication are some of the benefits offered by these technologies.

However, the cost constraints linked with the biopharmaceutical substances is also a limit for the growth of biopharmaceutical oral drug delivery market.

Key Players

AbbVie, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Amgen, Inc.
Catalent Inc.
Kemwell Bipharma.
Pfizer, Inc.
Novartis AG
Biocon
Sanofi
F. Hoffman-La Roche Ltd.
Novo Nordisk A/S.